Trial Profile
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary) ; Immune globulin
- Indications Agammaglobulinaemia; Immunodeficiency disorders
- Focus Pharmacokinetics
- Sponsors Grifols
- 01 Mar 2022 Results of pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing by using data from three studies including this study published in the International Immunopharmacology
- 16 Mar 2020 Results presented on 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 16 Mar 2020 Results assesseing the safety and tolerability of IGSC-C 20% and intravenous immune globulin infusion (human),10% caprylate/ chromatography purified (IGIV-C 10%) in participants with PI, presented at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology